Stayble Therapeutics AB (publ) (STABL.ST)

0.2495 0.0000 (0.00%) As of 03:28PM CEST. Market open.

Stayble Therapeutics AB (publ)

Lennart Torstenssonsgatan 6
Gothenburg 412 56
Sweden

https://www.staybletherapeutics.se

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 3

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Andreas Gerward M.Sc.	Co-Founder & CEO	N/A	N/A	1988
Mr. Mattias Munnich M.Sc.	Co-Founder	N/A	N/A	1979
Mr. Thomas Palsson M.Sc.	Chief Financial Officer	N/A	N/A	1952
Mr. Anders Lehmann Ph.D.	Chief Scientific Officer	N/A	N/A	1957

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Stayble Therapeutics AB (publ) develops injectable treatment for chronic pain triggered by disc degeneration. The company develops STA363, an injection into the disc that targets chronic low back and leg pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.

Corporate Governance

Stayble Therapeutics AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.